吉贝尔：2025年净利润2.59亿元，同比增长17.94%

Core Insights - The company reported a total operating revenue of 965 million yuan for the fiscal year 2025, representing a year-on-year growth of 7.63% [1] - The net profit reached 259 million yuan, showing a year-on-year increase of 17.94% [1] - Overall business performance during the reporting period was strong, driven by team building and market development efforts [1] Revenue and Profit Growth - The sales revenue of the main product, Niquilol tablets, maintained a rapid growth trend [1] - Both total operating revenue and net profit attributable to the parent company experienced growth [1] Research and Development Progress - The company is actively advancing the research and development of new drugs, including the antidepressant JJH201501 and the anti-tumor drug JJH201601 [1] - The Phase III clinical trial for the antidepressant JJH201501 has been successfully completed [1] - The Phase IIa clinical trial for the anti-tumor drug JJH201601 is progressing in an orderly manner [1]